{"id":790371,"date":"2024-11-25T08:10:21","date_gmt":"2024-11-25T13:10:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/"},"modified":"2024-11-25T08:10:21","modified_gmt":"2024-11-25T13:10:21","slug":"annovis-to-host-year-end-investor-webcast-on-december-11-2024","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/","title":{"rendered":"Annovis to Host Year-End Investor Webcast on December 11, 2024"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Nov.  25, 2024  (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST.<\/p>\n<p>\n        <b>Webcast Details:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Date:<\/b>      December 11, 2024<\/li>\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Time:<\/b>      4:30 PM EST<\/li>\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Registration      Link:<\/b><br \/>\n          <a href=\"https:\/\/zoom.us\/webinar\/register\/WN_9AGUHZA2SZOvi-Q7HJgVKQ\" rel=\"nofollow\" target=\"_blank\"><br \/>\n            <b>Register      Here<\/b><br \/>\n          <\/a>\n        <\/li>\n<\/ul>\n<p>Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the company&#8217;s recent achievements, ongoing clinical programs, and strategic initiatives for 2025. <\/p>\n<p>Key topics will include:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Clinical      Progress:<\/b> Updates on Phase 3 studies for Parkinson&#8217;s and Alzheimer&#8217;s      diseases.<\/li>\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Regulatory      Milestones:<\/b> Insights into interactions with the U.S. Food and Drug      Administration (FDA) and upcoming submissions.<\/li>\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Financial      Overview:<\/b> Summary of the company&#8217;s financial health and funding      strategies.<\/li>\n<li style=\"margin-top:0in;margin-bottom:8pt\">\n          <b>Strategic      Outlook:<\/b> Plans for advancing neurodegenerative disease therapies in      the coming year.<\/li>\n<\/ul>\n<p>\n        <br \/> Investors and interested parties are encouraged to register in advance through the provided <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ur9EGf03tuDTFTkPHFqYQC9jXGSIhU-T4DrmIsdA5Y-kn1A5gxUXMF-XqRPkxOyw1AA6zPuct89HuUuBnr8HtTa7oXTQWqU3lIeBcfXuHAOUT3fHGxIW_lPU0Ssna-_o\" rel=\"nofollow\" target=\"_blank\">Zoom link<\/a>. To address the high volume of recent inquiries, Annovis will strive to answer as many questions as possible during the Q&amp;A session following the presentation. Participants are invited to submit their questions in advance to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l-_CDw2IjSIChaRYsIOa0eTwVswSOK1rwK3ktipCaq9m_R2tbU8Uu-VHYqZ58jlc8VtSYGjWlySjyuYwSfW1ycwmjcT1ZyTm4SEM9Q0Fk6k=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a>.<\/p>\n<p>\n        <b>About Annovis <\/b>\n      <\/p>\n<p>Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company\u2019s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eCj0IUIBnwPMeb1oH5uzPy46jljs3GGPqyyQq9uJmjgZDOEVaZecetIjWi9Oyy1c8aSdYHzdc61lJ-X68WYY0-ZCYa-GGT_HORLeSVSRTnM8C525dfw4-z4s1ADefVMV_X5V5TihxUaUbrVUfyqpp87rLLl0uT45vyj2N_G_-InOKVv5-pMVL_V3bZ-LIXzuNnvuZocOA47EluW21jLfy3pXZfnsw2iCkzaYJrFYk9FwRr0NP_W4SuCOmTTnokZHp13M3QfFHYXFNa_1dUfyru0gNM5D-STSbvjph2QU8h7jV1Q1auS3g99Us9eoU5fLIu_Np2BhVzt0iPGMBxeYA6GVoyT2_QYAH270kcooW2DjT0-AlBDUK25CEdiAHgef8OvCZgYwsP1s9G4q02YB-xubN_xlmdb21nVN_u0R6M6TK5pkOb7ybeOMuOCC1OBiEA-QTrHiNyUhDTlkOBLZYaJDqtvCJ7FWaTO2xkpEp2U=\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yO-DpsdLzRMN3AtSIYml-qW7m6vqJGDk8I5mfGK3KFfan-GvDjsoW4-Y3-iAe1fuMEgRSfSMcvPoxIErvr8xbqqD_biJ1xYMohMUzDQcn4mYAqf3AZMgq_pRPmyA5nCFkBQS8VHrf5FOrTitMFfLC0it4q6HSHqeHJaBqbyk4AKYtmliGgEEJFV_ITaA-C6BHrXzWG6xjmn0o3tpTkFVj6QH1iVfMjLEYrkL1n6731MCD4vrlkXCi1vx6AD4BJR-y8lhz3qxu551BvfOVy2aei6c_DZ5FynPwqhF3Vuhd8AjyUG8R69ky3lXGOfSEINw3O6EOpzC-xL3hfb8_wtzC46XDXStulbJrvXBl-f8MmIkRFN3FXW9q5jFVPJfpt5YSMdThYWknNBgU51TuvUzpWXO2fNWcceRVizogJJla-GAjBZrsUQKRlVN8yLpJSfL58pUlLXa4RgLFTtFVtQ7HPmHws9emQkjp0GBY6OVq2c=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FMdxuFEoRX-TOK-gXcpHFpDZbqcZi0Wri1ZCQdCkUgdtceEM_36tiuv4OWeZ2wcw8BBNzT2UagMHiqsk6KLCaiu2jdJ_XZb_zoUMF5oNNHs5_ahSGRvdH8aq1SV6dbTgRqHyjmAWLsWFVxIhlfV-9_3fpKPLZqTs1jD_0CpXpoUjyCzGYQmR6iwTfuu8DItbtjnfUk0RrVuJMAQwlSQT0K8PJNlAitZMdqn4qL9R3umSFyZu42yUJsIoUc7nsuFrdXORFfzXJ-xdhh2Aw-oK3KDFbspS9YU-mk4qYmfOskwlEckcvfXKt1U_OuR75Vsf-UyHPXu4xPiHFb_KESrqSwz1z03EDqFv2089FDsThedWQAX39ikimM3a5Up4RJ1FZSBWJdJJ3GKqRO-OfyEB53YKkjFtELAFMrbHvANTK9K_qj7VewP5fX-JoUPAnIi9\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x20evj0JAQk1f0IgBIfLtRuaGgbMnqU54Au5I3wtwWE3YRJzWIKIm36XAhbIMcOpQ1CJxbgkU36vfxWH3cq5UVK_mY4T_bxK1uYqO-yXBTV2EYyO568nRBoDabl09sbtGA8kiUc__WJPzMJXVS_3sW3jCWXnzVt1j5AL6vGjbUhGIy2fYj6SdZlaP3zqGmyoYJN8Zz2yXprHQ9dXXHZjeVNP2lfLlGUYcoj4_4zfCAArgah7tdMHnac3twuBril-M2KmJhTTcG0xd2P7raITe_vhXGpZq5JAZTrK8O72YrG-IgV7K49e2sTcnX6Pecs1kV8uduzX907XnOMP2BkRQTIpa9tIruEwbHanJBS50R6-oxawWDiUyD63dEWqmnv9\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <b>Investor Alerts<\/b>\n      <\/p>\n<p>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xNFrWn5AFOaxvhMcNboP2JBG4ol-oEEDN7vYBBFlfSZAmorDZThIx5lhqINFePwI2MD7ZnFZ7Po1NV_N20EZLr4-4Z88r5T-stFLHVeyAoiL7PGfnBJJppDznl4nGCfcTKJuDLLc5mLG-Zh26yJXeBK5ybcqo_UWcLPdk3mU70t4_J9zxIziRxXMvGgEnTNGXJtDlquKvmwrdYby3AvA5uq24CAdzonvU7ZOWbkep6KCMcaWiFp3bXJnNA-mCPEnRgSb_6Lu3n0uXWo083n82pbLIHDseQdyuCU3dBS2E6Ui6P6D2ns2lZc-U0Du1RvEBUIjpalDDW026xG4Z-7_7r4wqXT-cW7eq7ni_ZCcw0uI0iirahKW0i2FB_nhTR6FCdyMxHjZXBF73Uq9o-NV7iE5CRIkYeaaCnSJNl3nNRm6qWa3L0bWOlDy6eh3LPXYUluBoaLgm8jQgQlh7CG5moxFGZdweJv25o5ZBppAP-MTBI_K0hjraiUXo2jf7euBnW3o8pn08IwVBtofG_S4osW1wU5habCfwBmC82JkVx-_B7wEEqbNtGGs7DCBJ4Fa8k1pTH6aGggqPcFWiS52agTUMhHRsjJwJKkOAIEeDToT9bfm47kIjpoyPiSnvNLu\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>. Additionally, we invite you to explore our updated\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mN6U-ydf4Dw43Wp1QLO51g9yz0qUnNeAT90MT9OGBITXuCj1vVQOhf4K1kPnOLlC3-ncGvwAsVZfKPnCVLHQOD1Nhq_u-UBZ52my721OCRunwgEJz0O63VvHXriVVzMuNGdqkn4B5BfAR_EuJG4uI2Nd9SuEw7_npAaqMGj_K4RNjU2kOHuWKg2ZxWVfKF6wgSSMjcx-s857IdJWm04xTAjqaBgOl0tLrhOx5ZBRHh3WGFQpeuGEfodUl2xvzRnmho7AUW6v9lNFwJDG8CHF8RsXM1XaP0M3Z0rAVAwOeHW79UqvSdzA3Sa_TydaenmUMgsHK5znW6BiOphPwjepxYyNObgleb_auWhnwQ6aCiLjhlhnSkdSp35h8kNxM-jOeiTm-doWRuKJACrCdICuumMALBXTcgdnx2hz8154QwutE91kW_n8WDFLfa8sw3g0bLPrnAbPjkb1AJHJl6h1tLDiJKN7zxcV5JNyz1ke6Q5W4uMhv2DLsUwq11vM0N6W\" rel=\"nofollow\" target=\"_blank\">investor website<\/a>, which provides comprehensive access to company news, financial reports, and other key information.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains &#8220;forward-looking&#8221; statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company&#8217;s plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company&#8217;s clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company&#8217;s periodic filings with the SEC, including those listed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n<p>\n        <b>Contact Information:<\/b><br \/>\n        <br \/> Annovis Bio Inc.<br \/> 101 Lindenwood Drive<br \/> Suite 225<br \/> Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eCj0IUIBnwPMeb1oH5uzPxWSpucMmiiMyZTdOsDOfbKQCo6daT3hRkhGrRS1ODhw2OkSuRH0g20rsHR8wwiPHvc34gXiJE74evN0cafIwOYegQMSilpxx0G2mWsdYb_gKk60h0Z-0nnowxPDk3Be8hMbfeIvBYM9V_qNYtwREIvEsqhYC6tt27w_ayPa8xPYI5mhHnESc8wd81EVjL9nJhc58H7-suMUtKr386f1EGNrwpoq88-hGvCbXOhT-JwSfQ5PeEB--9fgQI26kPIdR8J84ZHzy8Ed9Uai_2ZObOhtfappj7Jk5rKG9B9kN7oWkM0zRvRZP2qoR4f2ICyLUUfKn4QUBRUeqMg7elR9ABjmYjDqqXxtDZjqj6uzuSVgFWopUPZRCgEaq5jgqco1EmWSiKR8EhSZtJFWl2tx0cfdIID8Vf7dgc3aaOXLr7vAmt9g2iydswRHaHL8jekaJ9CKdERzcMVMGmZbsKGHy2c=\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/> Scott McGowan<br \/> InvestorBrandNetwork (IBN)<br \/> Phone: 310.299.1717<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eCj0IUIBnwPMeb1oH5uzP1qFZ08oYJBKj_5DRQ4fzZHhtPFZcIS9xRB66jyVGlvw-igPHBAVa0DwPPp-7UvldJS_SxJDv5Sf9t_kwXhRfivXwn3zYTM1c2-1eFsBnj6FlZm2UsBGst5EijZjXSJCPL8U6wyUo7Gw3pNR2z4hd-6vWftdJg_emrDAD1KCK_tKhHqbVkfTyxdzbtZOiD2v6_R0x2J8xT0dAVkm0neCXbPk08frZKORL_yr75Vx-9j7E9l7fMzTtuXl7CFiwgkMKxPybBc6KGJcAQd1Yd_R68v6HcKcmoXZkOvoL22w-bYeJjTHQlnYt17pbRt0A37VgewN8eYCQCRrycc0GKhhIZE=\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com\/investors-relations<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fXm17CwNu6xUQTP47A0qBUtf1dNaiu96F3YgC6GKKunaM0pXtytCkTI_kPJkRd4YJ18bI6sikTpQjQXNeMP10eoxSiqcnXGxnKuHgbzpnZHEkGpx7QvvJAqc5ILV518o9n0rnwu2AMY0Q2b03UPPKJmuG6SHSny3ymlYi48go6Itpv7XK-QAi3obQTfV_GsBOQOa7epcUIxRNRCF-uzSLMi7MHji9UuXWkQZ5vXhFfsttUaQy7lFpdkFMom94azqVBiro4rc7iWYfoLQyEVjsw==\" rel=\"nofollow\" target=\"_blank\">IR@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzAyZTA3YTctMDJhZS00OWE5LWI1OTUtODI3NDMyMWYzMzFjLTUwMDA3ODQ2NQ==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. Webcast Details: Date: December 11, 2024 Time: 4:30 PM EST Registration Link: Register Here Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the company&#8217;s recent achievements, ongoing clinical programs, and strategic initiatives for 2025. Key topics will include: Clinical Progress: Updates on Phase 3 studies for Parkinson&#8217;s and Alzheimer&#8217;s diseases. Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (FDA) and upcoming submissions. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis to Host Year-End Investor Webcast on December 11, 2024&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-790371","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. Webcast Details: Date: December 11, 2024 Time: 4:30 PM EST Registration Link: Register Here Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the company&#8217;s recent achievements, ongoing clinical programs, and strategic initiatives for 2025. Key topics will include: Clinical Progress: Updates on Phase 3 studies for Parkinson&#8217;s and Alzheimer&#8217;s diseases. Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (FDA) and upcoming submissions. &hellip; Continue reading &quot;Annovis to Host Year-End Investor Webcast on December 11, 2024&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T13:10:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis to Host Year-End Investor Webcast on December 11, 2024\",\"datePublished\":\"2024-11-25T13:10:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/\"},\"wordCount\":529,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/\",\"name\":\"Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\",\"datePublished\":\"2024-11-25T13:10:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis to Host Year-End Investor Webcast on December 11, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/","og_locale":"en_US","og_type":"article","og_title":"Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk","og_description":"MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; via IBN \u2013 Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. Webcast Details: Date: December 11, 2024 Time: 4:30 PM EST Registration Link: Register Here Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the company&#8217;s recent achievements, ongoing clinical programs, and strategic initiatives for 2025. Key topics will include: Clinical Progress: Updates on Phase 3 studies for Parkinson&#8217;s and Alzheimer&#8217;s diseases. Regulatory Milestones: Insights into interactions with the U.S. Food and Drug Administration (FDA) and upcoming submissions. &hellip; Continue reading \"Annovis to Host Year-End Investor Webcast on December 11, 2024\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-25T13:10:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis to Host Year-End Investor Webcast on December 11, 2024","datePublished":"2024-11-25T13:10:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/"},"wordCount":529,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/","name":"Annovis to Host Year-End Investor Webcast on December 11, 2024 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==","datePublished":"2024-11-25T13:10:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI3ODgxOSM2NTk3NjA2IzUwMDA3ODQ2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-host-year-end-investor-webcast-on-december-11-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis to Host Year-End Investor Webcast on December 11, 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=790371"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790371\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=790371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=790371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=790371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}